Furthermore, Lenvatinib was also found to have other pathways in the modulation of antitumor immunity, including the reduction of tumor PD-L1 expression levels and Treg differentiation by blocking FGFR4 (26) and reducing the Treg proportion through TGF-β pathway inhibition (27). This evidence concerns the gene FGFR4 and neoplasm.